Login
ZIOPHARM Oncology NASDAQ: ZIOP
ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology
| Name | ZIOPHARM Oncology |
| Ticker | ZIOP |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
|
Price
52W Low/High |
2.24
2.09 / 5.60 |
| Momentum | Sharp Down |
| Market cap | 481 M |
| 1Y Total Return |
-27.51 %
Subpar |
| 1Y Volatility |
75.91 %
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology
Details
| Ticker | ZIOP |
| Name | ZIOPHARM Oncology |
| ISIN | US98973P1012 |
| CUSIP | 98973P101 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
| Country | USA |
| Currency | U.S. Dollar |
Share as of 07/23/2021
| Close Price | 2.24 |
| 52W Low/High | 2.09 / 5.60 |
| Market cap | 481 M |
| 1Y Total Return |
-27.51 %
Subpar |
| 1Y Volatility |
75.91 %
High Risk |
| Beta | 6.22 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | - |
| Cash from Op. / Cur. Liabilities | -3.29 |
| Diluted Earnings / Share | -0.40 |
| ROE | - |
| ROIC | -836.8 % |
| Price / Revenue | - |
| Price / Book | 4.5 |
| Price / CF | -7.7 |
| Current Ratio | 5.9 |
| Cur.Liabilities / Tot.Liabilities | 0.8 |
| Financial Leverage | 0.04 |
| in Mils USD |
rolling-year up to March
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Revenue |
0
|
0
|
0
|
5
|
6
|
6
|
|
| Gross Profit |
-
|
-
|
-
|
5
|
6
|
6
|
|
| R&D |
53
|
42
|
33
|
43
|
160
|
43
|
|
| EBITDA |
-82
|
-122
|
157
|
-54
|
-168
|
-54
|
|
| Operating Income |
-83
|
-63
|
-51
|
-56
|
-167
|
-54
|
|
| Net Income exc. Extra |
-
|
-
|
157
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
214
|
200
|
161
|
141
|
131
|
130
|
|
| EPS exc. Extra |
-0.40
|
-0.69
|
1.04
|
-0.53
|
-1.38
|
-0.41
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Total Assets |
128
|
198
|
84
|
87
|
94
|
142
|
|
| Cash, Eq & Invt ShortTerm |
100
|
171
|
52
|
51
|
67
|
125
|
|
| Total Current Assets |
113
|
192
|
74
|
72
|
93
|
140
|
|
| Total Non-Current Assets |
16
|
7
|
9
|
15
|
2
|
1
|
|
| Intangibles |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
23
|
18
|
9
|
62
|
60
|
64
|
|
| Total Current Liabilities |
19
|
17
|
8
|
10
|
17
|
17
|
|
| Long Term Debt |
4
|
1
|
1
|
52
|
42
|
47
|
|
| Shareholder equity |
106
|
180
|
74
|
-123
|
-95
|
78
|
|
| Cash Flow | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Cash from Operations |
-62
|
-41
|
-41
|
-59
|
-57
|
-6
|
|
| Depreciation |
2
|
1
|
1
|
0
|
0
|
0
|
|
| Cash from Investing |
-10
|
-1
|
-0
|
-1
|
-1
|
-1
|
|
| Capex |
10
|
1
|
0
|
1
|
1
|
1
|
|
| Cash from Financing |
1
|
161
|
41
|
45
|
-1
|
2
|
|
| Stock Issued |
1
|
161
|
-1
|
45
|
-1
|
2
|
|
| Debt (LT) Issued |
0
|
0
|
47
|
0
|
0
|
0
|
|
| Free Cash Flow |
-94
|
-114
|
156
|
-62
|
-168
|
-49
|
|
| Ratios | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
5.9
|
11.6
|
8.9
|
7.2
|
5.3
|
8.1
|
|
| Financial Leverage D/E |
0.04
|
0.01
|
0.01
|
-
|
-
|
0.00
|
|
| Return on Capital Avg |
-836.8 %
|
-719.1 %
|
631.0 %
|
-299.6 %
|
-3,413.2 %
|
-
|
|
| Return on Shareholder Equity |
-
|
-
|
-592.5 %
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available